BioMAP® Fibrosis Panel

BioMAP® Fibrosis Panel
Version:
20875

Year:
2018

Fibrosis can occur in almost any tissue, with disease severity ranging from relatively innocuous scarring to more severe and life threatening conditions in the lung, liver, or kidneys. The complexity of the cellular and molecular mechanisms implicated in the establishment and progression of fibrosis make it difficult to find assays to identify potential therapeutics. As focus moves away from single cell assays and animal models that do not accurately predict drug effects in patients, more innovative and clinically relevant in vitro screening methods are needed. The BioMAP Fibrosis Panel can evaluate the anti-fibrotic potential of early pipeline compounds using more physiologically relevant in vitro human disease models and accelerate compounds along the drug discovery pipeline towards clinical success.